Blau Farmacêutica S.A. (BVMF:BLAU3)
Brazil
· Delayed Price · Currency is BRL 13.18
+0.41 (3.21%)
May 13, 2025, 10:44 AM GMT-3
Blau Farmacêutica Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,768 | 1,754 | 1,373 | 1,407 | 1,366 | 1,182 | Upgrade
|
| Revenue Growth (YoY) | 19.92% | 27.81% | -2.44% | 2.96% | 15.62% | 20.90% | Upgrade
|
| Cost of Revenue | 1,079 | 1,096 | 882.38 | 739.03 | 700.47 | 625.84 | Upgrade
|
| Gross Profit | 688.58 | 658.75 | 490.25 | 667.88 | 665.93 | 555.97 | Upgrade
|
| Selling, General & Admin | 305.75 | 303.77 | 150.28 | 213.85 | 201.77 | 161.36 | Upgrade
|
| Other Operating Expenses | -32.34 | 1.5 | -117.75 | 1.83 | 5.41 | 4.93 | Upgrade
|
| Operating Expenses | 288.1 | 319.95 | 41.97 | 215.69 | 209.31 | 166.83 | Upgrade
|
| Operating Income | 400.48 | 338.8 | 448.28 | 452.19 | 456.62 | 389.13 | Upgrade
|
| Interest Expense | -49.01 | -58.31 | -32.11 | -32.43 | -26.8 | -15.32 | Upgrade
|
| Interest & Investment Income | 46.69 | 46.69 | 55.8 | 70.22 | 34.95 | 5.23 | Upgrade
|
| Earnings From Equity Investments | - | - | 0.16 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -18.89 | -18.89 | -8.6 | -4.45 | 1.23 | -24.77 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.14 | -6.39 | -10.3 | -16.97 | 16.46 | -0.63 | Upgrade
|
| EBT Excluding Unusual Items | 369.13 | 301.89 | 453.23 | 468.56 | 482.47 | 353.64 | Upgrade
|
| Other Unusual Items | -10 | -10 | -119 | - | - | - | Upgrade
|
| Pretax Income | 359.13 | 291.89 | 334.23 | 468.56 | 482.47 | 353.64 | Upgrade
|
| Income Tax Expense | 94.59 | 78.36 | 86.74 | 108.07 | 158.6 | 99.31 | Upgrade
|
| Earnings From Continuing Operations | 264.54 | 213.53 | 247.49 | 360.49 | 323.86 | 254.33 | Upgrade
|
| Minority Interest in Earnings | 3.51 | 3.68 | 2.32 | 2.88 | 1.36 | - | Upgrade
|
| Net Income | 268.05 | 217.21 | 249.81 | 363.37 | 325.22 | 254.33 | Upgrade
|
| Net Income to Common | 268.05 | 217.21 | 249.81 | 363.37 | 325.22 | 254.33 | Upgrade
|
| Net Income Growth | 12.65% | -13.05% | -31.25% | 11.73% | 27.87% | 27.01% | Upgrade
|
| Shares Outstanding (Basic) | 179 | 178 | 178 | 178 | 179 | 148 | Upgrade
|
| Shares Outstanding (Diluted) | 179 | 178 | 178 | 178 | 179 | 158 | Upgrade
|
| Shares Change (YoY) | 0.26% | - | -0.08% | -0.87% | 13.84% | 4.39% | Upgrade
|
| EPS (Basic) | 1.50 | 1.22 | 1.41 | 2.04 | 1.81 | 1.72 | Upgrade
|
| EPS (Diluted) | 1.50 | 1.22 | 1.41 | 2.04 | 1.81 | 1.61 | Upgrade
|
| EPS Growth | 11.52% | -13.05% | -31.19% | 12.69% | 12.33% | 21.68% | Upgrade
|
| Free Cash Flow | 300.85 | 364.53 | 71.14 | 29.24 | 5.93 | 143.91 | Upgrade
|
| Free Cash Flow Per Share | 1.68 | 2.05 | 0.40 | 0.16 | 0.03 | 0.91 | Upgrade
|
| Dividend Per Share | - | - | 0.384 | 0.644 | - | - | Upgrade
|
| Dividend Growth | - | - | -40.40% | - | - | - | Upgrade
|
| Gross Margin | 38.95% | 37.55% | 35.72% | 47.47% | 48.74% | 47.04% | Upgrade
|
| Operating Margin | 22.66% | 19.31% | 32.66% | 32.14% | 33.42% | 32.93% | Upgrade
|
| Profit Margin | 15.16% | 12.38% | 18.20% | 25.83% | 23.80% | 21.52% | Upgrade
|
| Free Cash Flow Margin | 17.02% | 20.78% | 5.18% | 2.08% | 0.43% | 12.18% | Upgrade
|
| EBITDA | 442.95 | 378.91 | 478.15 | 469.62 | 474.85 | 404.94 | Upgrade
|
| EBITDA Margin | 25.06% | 21.60% | 34.83% | 33.38% | 34.75% | 34.26% | Upgrade
|
| D&A For EBITDA | 42.47 | 40.11 | 29.87 | 17.43 | 18.22 | 15.81 | Upgrade
|
| EBIT | 400.48 | 338.8 | 448.28 | 452.19 | 456.62 | 389.13 | Upgrade
|
| EBIT Margin | 22.66% | 19.31% | 32.66% | 32.14% | 33.42% | 32.93% | Upgrade
|
| Effective Tax Rate | 26.34% | 26.85% | 25.95% | 23.06% | 32.87% | 28.08% | Upgrade
|
Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.